HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM)

NCT06913959 | Not Yet Recruiting DMC

• 1 other identifier: ANRS0098s
• Study Type: observational
• Target: 220
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of the study is to study the genotypic characteristics of HIV-1 non-M circulating in the whole Cameroon and their genetic evolution.

Conditions

HIV Infection

Keywords

HIV genetic diversity; HIV-1 non-M variants

Outcome Measures

Primary Outcomes (1)

• Prevalence of non-M HIV-1 in Cameroon

  Number of participants infected with non-M HIV-1 included compared to the total expected number of inclusions

  1 day

Secondary Outcomes (1)

• Investigate the current molecular epidemiology of resistance in non-M HIV-1 variants in Cameroon

  1 Day

Other Outcomes (1)

• Study the current molecular epidemiology of HIV 1 non-M variant resistance in Cameroon

  1 day

Study Arms (2)

Retrospective

Dried Blood Spot samples tested positive for HIV during the previous national epidemiologic surveys Demographic health surveys in Cameroon

Diagnostic Test: Prospective

Prospective

Individuals who came to Center Pasteur in Yaounde or Garoua for HIV screening or viral load monitoring

Diagnostic Test: Prospective

Interventions

Prospective DIAGNOSTIC_TEST

Blood samples will be collected in order to meet the objectives of this substudy and possibly for complementary research

Prospective; Retrospective

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Retrospective phase : Dried Blood Spot samples tested positive for HIV during the Demographic health surveys in Cameroon 2011 and 2018 surveys, serotyping for HIV. Prospective phase : Individuals who came to Center Pasteur Cameroon in Yaoundé or Garoua for HIV screening or viral load monitoring, serotyping of HIV for positive samples.

You may qualify if:

• All available samples tested positive for HIV during the national Health survey of Cameroon in 2011 And 2018
• All Individuals who came to Centre Pasteur in Yaoundé or Garoua for HIV screening or viral load monitoring.

You may not qualify if:

• Insufficient quantity or degraded Dried Blood Spot samples
• All HIV-positive individuals aged less than 21 years, infected with a Group M HIV-1 virus, or those who refused to participate in the study

Sponsors & Collaborators

• ANRS, Emerging Infectious Diseases: lead
• University Hospital, Rouen: collaborator
• Centre Pasteur du Cameroun: collaborator

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples, 2x 5ml EDTA (ethylenediaminetetraacetic acid)

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Central Study Contacts

Mariam Gharib, PhD

CONTACT

0144236442; mariam.gharib@inserm.fr

Elodie Alessandri-Gradt, ParmD PhD

CONTACT

+33232855885; elodie.alessandri@chu-rouen.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 31, 2025
• First Posted: April 6, 2025
• Study Start: June 30, 2025
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: April 8, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share